Shopping Cart
- Remove All
- Your shopping cart is currently empty
CMI-392 is a dual inhibitor of 5-lipoxygenase and a receptor antagonist for platelet-activating factor (PAF) with IC50 values of 100 nM and 10 nM, respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 2.014 € | 8-10 weeks | |
50 mg | 2.641 € | 8-10 weeks | |
100 mg | 3.515 € | 8-10 weeks |
Description | CMI-392 is a dual inhibitor of 5-lipoxygenase and a receptor antagonist for platelet-activating factor (PAF) with IC50 values of 100 nM and 10 nM, respectively. |
Targets&IC50 | PAF:10 nM, 5-LOX:100 nM |
In vivo | In the acute and chronic TPA models, topical treatment with CMI-392 results in a significant decrease of ear weight, inflammatory cell infiltration, and histological examination. The ED50 for PAF-induced mouse hemoconcentration and arachidonic acid-induced mouse ear edema are 2.2 and 1.8 mg/kg, respectively. |
Molecular Weight | 633.15 |
Formula | C31H37ClN2O8S |
Cas No. | 205654-37-1 |
Relative Density. | 1.35 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.